the confusion here comes from how loosely ‘additive’ gets thrown around in these threads. the 503A additive pathway isn’t a blanket exemption. it requires that the additive produce a clinical difference for an identified patient - meaning a prescriber has documented why that specific formulation is necessary for that specific person. it’s not “we put B12 in it, therefore we’re legal forever.” FDA’s position, which has been consistent if not always loudly stated: just including an additive doesn’t automatically satisfy the clinical difference standard. BPI getting threatened per-vial strongly suggests FDA was reviewing actual formulations and not accepting the additive argument at face value. what changed: during the shortage period, 503As had broader cover. shortage ended (officially), so now the additive pathway has to actually hold up to scrutiny. some pharmacy ops were relying on the additive framing as a catch-all rather than building genuine clinical difference documentation. this doesn’t mean all compounded tirz is gone. 503As with real clinical difference documentation, patient-specific Rxs, and pharmacists who can defend the formulation are in a different position than bulk-compounding shops that were treating the additive rule as a loophole. the category is not the tell. the paperwork is.
“the category is not the tell. the paperwork is” is the right framing but I’d push on one piece. the clinical difference standard isn’t just documentation existing, it’s whether the documentation reflects an actual prescriber judgment about that specific patient. a lot of the additive-as-loophole shops were generating boilerplate clinical difference language that was essentially identical across every patient Rx, which is the part FDA seems to be flagging. if every B12-additive patient at a given pharmacy has the same justification text, that’s not patient-specific clinical difference, that’s a template, and a reviewer can spot it in five minutes. the other piece worth naming is the timeline asymmetry. shortage officially ended October 2024, but the enforcement posture didn’t shift uniformly. some 503As pivoted to genuine clinical difference workflows months before the resolution, some are still operating on shortage-era assumptions, and the BPI action suggests FDA is sorting through that distribution now rather than treating all 503As the same. for T2D patients specifically this matters bc the prescriber documentation is more defensible when there’s a real clinical rationale, dose titration outside commercial vial sizes, allergy to an excipient, etc, versus weight management Rxs where the clinical difference often reduces to cost or convenience, which isn’t what the standard contemplates. so I’d refine the framing slightly: the paperwork is the tell, but only if the paperwork reflects actual prescriber judgment per patient. boilerplate documentation is functionally the same as no documentation once a reviewer is actually looking.
Something most patients on compounded tirz won’t find out until access suddenly stops: there’s no real way to assess your prescriber’s documentation quality from the patient side. You can’t see whether your Rx was patient-specific reasoning or the same boilerplate copied across hundreds of files. What feels particularly unfair is that someone who’s been carefully logging their titration and response pattern for months still bears the consequences of paperwork they never saw and couldn’t have evaluated. That tracking data isn’t a legal defense, but a prescriber trying to rebuild a genuine clinical rationale has something real to work with rather than starting from a checkbox.
the asymmetry in “tracking data isn’t a legal defense” is the part that stings. patient-side logs can reconstruct a clinical rationale after the fact but they can’t audit whether one ever existed in the file, which means the people most engaged in their own care are the ones most exposed to documentation gaps they had no way to see.
“pharmacists who can defend the formulation” is doing a lot of work there, bc FDA hasn’t published a clear standard for what sufficient clinical difference documentation actually looks like. fwiw the steel-man is real: documentation quality obviously varies, and shops with patient-specific Rxs and genuine formulation rationale are in a better position than bulk operations. but “better position” and “defensible position” aren’t the same thing when the regulator hasn’t operationalized the standard you’re being measured against.
edit: forgot to add
The part worth adding: “patient-specific Rxs” as a protective factor is only as strong as the prescriber’s documentation, and that’s exactly where the enforcement pressure is likely to land next. A pharmacy that built real clinical difference files is probably fine. A prescriber who rubber-stamped “patient requires B12 additive” for 300 patients without individualized rationale is a different risk profile, and the compounding pharmacy holding those scripts may not know which category their prescribers fall into until an audit.